Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Xenical (orlistat) reduces blood lipid levels by 10%; NDA filing before year-end.

Executive Summary

ROCHE XENICAL (ORLISTAT) REGIME PRODUCES 10% BLOOD LIPIDS DECREASE in some obese patients during a one-year Phase III study of the pancreatic lipase inhibitor, Roche Obesity Program/Clinical Science Leader Jonathan Hauptman, MD, reported at a "Pharma Research Press Day" Oct. 4 in Basle, Switzerland. Hauptman said patients with elevated low-density lipoprotein levels had a "very rapid and very good response" to Xenical, with about a 10% decrease in lipid levels compared to those patients on placebo, who experienced a "progressive increase" in levels after four weeks, with levels "moving up and down."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel